{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:14:46Z","timestamp":1794284086063,"version":"4.9.0"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41380-024-02709-z","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T03:03:12Z","timestamp":1725418992000},"page":"272-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Alzheimer\u2019s disease biomarkers and their current use in clinical research and practice"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4816-9457","authenticated-orcid":false,"given":"Tai R.","family":"Hunter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Tovar-Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-0589","authenticated-orcid":false,"given":"Fernanda G.","family":"De Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"2709_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","volume":"67","author":"A Kumar","year":"2015","unstructured":"Kumar A, Singh A, Ekavali. A review on Alzheimer\u2019s disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67:195\u2013203.","journal-title":"Pharmacol Rep"},{"key":"2709_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc. 2011;7:280\u201392.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"2709_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"2709_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement"},{"key":"2709_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA\u2010AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"2709_CR6","doi-asserted-by":"crossref","unstructured":"Jack Jr. CR, Andrews JS, Beach TG, Buracchio T, Dunn B, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20:5143\u201369.","DOI":"10.1002\/alz.13859"},{"key":"2709_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1212\/WNL.0b013e3181b16431","volume":"73","author":"CR McDonald","year":"2009","unstructured":"McDonald CR, McEvoy LK, Gharapetian L, Fennema-Notestine C, Hagler DJ, Holland D, et al. Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology. 2009;73:457\u201365.","journal-title":"Neurology"},{"key":"2709_CR8","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1073\/pnas.052587399","volume":"99","author":"RI Scahill","year":"2002","unstructured":"Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer\u2019s disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA. 2002;99:4703\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2709_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer\u2019s disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology"},{"key":"2709_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0306-4522(99)00476-5","volume":"95","author":"M Bobinski","year":"1999","unstructured":"Bobinski M, de Leon MJ, Wegiel J, DeSanti S, Convit A, Saint Louis LA, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer\u2019s disease. Neuroscience. 1999;95:721\u20135.","journal-title":"Neuroscience"},{"key":"2709_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neuroimage.2007.08.042","volume":"39","author":"BC Dickerson","year":"2008","unstructured":"Dickerson BC, Fenstermacher E, Salat DH, Wolk DA, Maguire RP, Desikan R, et al. Detection of cortical thickness correlates of cognitive performance: reliability across MRI scan sessions, scanners, and field strengths. NeuroImage. 2008;39:10\u201318.","journal-title":"NeuroImage"},{"key":"2709_CR12","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/1531-8249(200004)47:4<430::AID-ANA5>3.0.CO;2-I","volume":"47","author":"RJ Killiany","year":"2000","unstructured":"Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer\u2019s disease. Ann Neurol. 2000;47:430\u20139.","journal-title":"Ann Neurol"},{"key":"2709_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1503\/jpn.180171","volume":"45","author":"S Lee","year":"2020","unstructured":"Lee S, Lee H, Kim KW. Magnetic resonance imaging texture predicts progression to dementia due to Alzheimer disease earlier than hippocampal volume. J Psychiatry Neurosci. 2020;45:7\u201314.","journal-title":"J Psychiatry Neurosci"},{"key":"2709_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.neuroimage.2011.01.050","volume":"56","author":"SG Costafreda","year":"2011","unstructured":"Costafreda SG, Dinov ID, Tu Z, Shi Y, Liu C-Y, Kloszewska I, et al. Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. NeuroImage. 2011;56:212\u20139.","journal-title":"NeuroImage"},{"key":"2709_CR15","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1001\/archneurol.2011.167","volume":"68","author":"MR Sabuncu","year":"2011","unstructured":"Sabuncu MR, Desikan RS, Sepulcre J, Yeo BTT, Liu H, Schmansky NJ, et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011;68:1040\u20138.","journal-title":"Arch Neurol"},{"key":"2709_CR16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1212\/01.WNL.0000110315.26026.EF","volume":"62","author":"CR Jack","year":"2004","unstructured":"Jack CR, Shiung MM, Gunter JL, O\u2019Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology. 2004;62:591\u2013600.","journal-title":"Neurology"},{"key":"2709_CR17","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1212\/WNL.56.10.1386","volume":"56","author":"JT O\u2019Brien","year":"2001","unstructured":"O\u2019Brien JT, Paling S, Barber R, Williams ED, Ballard C, McKeith IG, et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology. 2001;56:1386\u20138.","journal-title":"Neurology"},{"key":"2709_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7:367\u201385.","journal-title":"Alzheimers Dement"},{"key":"2709_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306\u201319.","journal-title":"Ann Neurol"},{"key":"2709_CR20","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/brain\/awn016","volume":"131","author":"MD Ikonomovic","year":"2008","unstructured":"Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer\u2019s disease. Brain. 2008;131:1630\u201345.","journal-title":"Brain"},{"key":"2709_CR21","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.neurobiolaging.2007.03.029","volume":"29","author":"A Forsberg","year":"2008","unstructured":"Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456\u201365.","journal-title":"Neurobiol Aging"},{"key":"2709_CR22","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0b013e3181b23564","volume":"73","author":"A Okello","year":"2009","unstructured":"Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, N\u00e5gren K, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology. 2009;73:754\u201360.","journal-title":"Neurology"},{"key":"2709_CR23","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/brain\/awp062","volume":"132","author":"CR Jack Jr","year":"2009","unstructured":"Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer\u2019s disease: implications for sequence of pathological events in Alzheimer\u2019s disease. Brain. 2009;132:1355\u201365.","journal-title":"Brain"},{"key":"2709_CR24","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.jalz.2018.06.2855","volume":"14","author":"R Laforce Jr","year":"2018","unstructured":"Laforce R Jr, Soucy J-P, Sellami L, Dallaire-Th\u00e9roux C, Brunet F, Bergeron D, et al. Molecular imaging in dementia: past, present, and future. Alzheimers Dement. 2018;14:1522\u201352.","journal-title":"Alzheimers Dement"},{"key":"2709_CR25","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/mp.2014.9","volume":"19","author":"PM Doraiswamy","year":"2014","unstructured":"Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry. 2014;19:1044\u201351.","journal-title":"Mol Psychiatry"},{"key":"2709_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/jnnp-2014-308094","volume":"86","author":"KT Ong","year":"2015","unstructured":"Ong KT, Villemagne VL, Bahar-Fuchs A, Lamb F, Langdon N, Catafau AM, et al. A\u03b2 imaging with 18F-florbetaben in prodromal Alzheimer\u2019s disease: a prospective outcome study. J Neurol Neurosurg Psychiatry. 2015;86:431\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2709_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"R Vandenberghe","year":"2010","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319\u201329.","journal-title":"Ann Neurol"},{"key":"2709_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging \u03b2-amyloid pathology. JAMA. 2011;305:275\u201383.","journal-title":"JAMA"},{"key":"2709_CR29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement. 2015;11:964\u201374.","journal-title":"Alzheimers Dement"},{"key":"2709_CR30","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","volume":"60","author":"P Giannakopoulos","year":"2003","unstructured":"Giannakopoulos P, Herrmann FR, Bussi\u00e8re T, Bouras C, K\u00f6vari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer\u2019s disease. Neurology. 2003;60:1495\u20131500.","journal-title":"Neurology"},{"key":"2709_CR31","doi-asserted-by":"publisher","first-page":"338ra66","DOI":"10.1126\/scitranslmed.aaf2362","volume":"8","author":"MR Brier","year":"2016","unstructured":"Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, et al. Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease. Sci Transl Med. 2016;8:338ra66.","journal-title":"Sci Transl Med"},{"key":"2709_CR32","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","volume":"78","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78:961\u201371.","journal-title":"JAMA Neurol"},{"key":"2709_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/ph14020110","volume":"14","author":"CVML Jie","year":"2021","unstructured":"Jie CVML, Treyer V, Schibli R, Mu L. TauvidTM: the first FDA-approved PET tracer for imaging tau pathology in Alzheimer\u2019s disease. Pharmaceuticals. 2021;14:110.","journal-title":"Pharmaceuticals"},{"key":"2709_CR34","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1007\/s00259-020-05156-4","volume":"48","author":"GN Bischof","year":"2021","unstructured":"Bischof GN, Dodich A, Boccardi M, van Eimeren T, Festari C, Barthel H, et al. Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer\u2019s disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging. 2021;48:2110\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2709_CR35","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41380-022-01875-2","volume":"28","author":"M-L Malarte","year":"2023","unstructured":"Malarte M-L, Gillberg P-G, Kumar A, Bogdanovic N, Lemoine L, Nordberg A. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer\u2019s disease, corticobasal degeneration and progressive supranuclear palsy brains. Mol Psychiatry. 2023;28:1272\u201383.","journal-title":"Mol Psychiatry"},{"key":"2709_CR36","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/jnnp.2007.127878","volume":"79","author":"P Edison","year":"2008","unstructured":"Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, et al. Amyloid load in Parkinson\u2019s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79:1331\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2709_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D\u2019Anna L, Huss A, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18:158\u201372.","journal-title":"Nat Rev Neurol"},{"key":"2709_CR38","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, the NFL Group Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 2019;76:1035\u201348.","journal-title":"JAMA Neurol"},{"key":"2709_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.604119","volume":"13","author":"F Dakterzada","year":"2021","unstructured":"Dakterzada F, L\u00f3pez-Ortega R, Arias A, Riba-Llena I, Ruiz-Juli\u00e1n M, Huerto R, et al. Assessment of the concordance and diagnostic accuracy between elecsys and lumipulse fully automated platforms and innotest. Front Aging Neurosci. 2021;13:604119.","journal-title":"Front Aging Neurosci"},{"key":"2709_CR40","volume":"13","author":"EAJ Willemse","year":"2021","unstructured":"Willemse EAJ, Tijms BM, van Berckel BNM, Le Bastard N, van der Flier WM, Scheltens P, et al. Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimers Dement Diagn Assess Dis Monit. 2021;13:e12182.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"2709_CR41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28:595\u20139.","journal-title":"Nat Biotechnol"},{"key":"2709_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40120-019-00164-5","volume":"8","author":"D Li","year":"2019","unstructured":"Li D, Mielke MM. An update on blood-based markers of Alzheimer\u2019s disease using the SiMoA platform. Neurol Ther. 2019;8:73\u201382.","journal-title":"Neurol Ther"},{"key":"2709_CR43","doi-asserted-by":"publisher","first-page":"105046","DOI":"10.1016\/j.ebiom.2024.105046","volume":"102","author":"J Therriault","year":"2024","unstructured":"Therriault J, Ashton NJ, Pola I, Triana-Baltzer G, Brum WS, Di Molfetta G, et al. Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer\u2019s pathology. eBioMedicine. 2024;102:105046.","journal-title":"eBioMedicine"},{"key":"2709_CR44","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton NJ, Puig-Pijoan A, Mil\u00e0-Alom\u00e0 M, Fern\u00e1ndez-Lebrero A, Garc\u00eda-Escobar G, Gonz\u00e1lez-Ortiz F, et al. Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement. 2023;19:1913\u201324.","journal-title":"Alzheimers Dement"},{"key":"2709_CR45","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H, Allu\u00e9 JA, Sarasa L, Eichenlaub U, et al. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol. 2021;78:1375\u201382.","journal-title":"JAMA Neurol"},{"key":"2709_CR46","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","volume":"18","author":"IMW Verberk","year":"2022","unstructured":"Verberk IMW, Misdorp EO, Koelewijn J, Ball AJ, Blennow K, Dage JL, et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease\u2013related blood-based biomarkers: results from the standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group. Alzheimers Dement. 2022;18:1484\u201397.","journal-title":"Alzheimers Dement"},{"key":"2709_CR47","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/359325a0","volume":"359","author":"P Seubert","year":"1992","unstructured":"Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer\u2019s \u03b2-peptide from biological fluids. Nature. 1992;359:325\u20137.","journal-title":"Nature"},{"key":"2709_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","volume":"13","author":"T Iwatsubo","year":"1994","unstructured":"Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A\u03b242(43) and A\u03b240 in senile plaques with end-specific A\u03b2 monoclonals: evidence that an initially deposited species is A\u03b242(43). Neuron. 1994;13:45\u201353.","journal-title":"Neuron"},{"key":"2709_CR49","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8:595\u2013608.","journal-title":"EMBO Mol Med"},{"key":"2709_CR50","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archgenpsychiatry.2011.155","volume":"69","author":"P Buchhave","year":"2012","unstructured":"Buchhave P, Minthon L, Zetterberg H, Wallin \u00c5K, Blennow K, Hansson O. Cerebrospinal fluid levels of\u03b2-Amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69:98\u2013106.","journal-title":"Arch Gen Psychiatry"},{"key":"2709_CR51","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673\u201384.","journal-title":"Lancet Neurol"},{"key":"2709_CR52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13195-020-00595-5","volume":"12","author":"JD Doecke","year":"2020","unstructured":"Doecke JD, Ward L, Burnham SC, Villemagne VL, Li Q-X, Collins S, et al. Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimers Res Ther. 2020;12:36.","journal-title":"Alzheimers Res Ther"},{"key":"2709_CR53","volume":"15","author":"JK Wisch","year":"2023","unstructured":"Wisch JK, Gordon BA, Boerwinkle AH, Luckett PH, Bollinger JG, Ovod V, et al. Predicting continuous amyloid PET values with CSF and plasma A\u03b242\/A\u03b240. Alzheimers Dement Diagn Assess Dis Monit. 2023;15:e12405.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"2709_CR54","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3:154\u201365.","journal-title":"Ann Clin Transl Neurol"},{"key":"2709_CR55","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1056\/NEJMoa2310168","volume":"390","author":"J Jia","year":"2024","unstructured":"Jia J, Ning Y, Chen M, Wang S, Yang H, Li F, et al. Biomarker changes during 20 years preceding Alzheimer\u2019s disease. N Engl J Med. 2024;390:712\u201322.","journal-title":"N Engl J Med"},{"key":"2709_CR56","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.jalz.2018.01.013","volume":"14","author":"SE Schindler","year":"2018","unstructured":"Schindler SE, Gray JD, Gordon BA, Xiong C, Batrla-Utermann R, Quan M, et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement. 2018;14:1460\u20139.","journal-title":"Alzheimers Dement"},{"key":"2709_CR57","volume":"13","author":"MR Campbell","year":"2021","unstructured":"Campbell MR, Ashrafzadeh-Kian S, Petersen RC, Mielke MM, Syrjanen JA, van Harten AC, et al. P-tau\/A\u03b242 and A\u03b242\/40 ratios in CSF are equally predictive of amyloid PET status. Alzheimers Dement Diagn Assess Dis Monit. 2021;13:e12190.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"2709_CR58","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk D, Blennow K, White LR, Launer LJ. CSF A\u03b2 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60:652\u20136.","journal-title":"Neurology"},{"key":"2709_CR59","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1111\/j.1471-4159.1993.tb09823.x","volume":"61","author":"M Vandermeeren","year":"1993","unstructured":"Vandermeeren M, Mercken M, Vanmechelen E, Six J, Van de Voorde A, Martin J-J, et al. Detection of proteins in normal and Alzheimer\u2019s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993;61:1828\u201334.","journal-title":"J Neurochem"},{"key":"2709_CR60","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/JAD-2000-23-402","volume":"2","author":"C Hesse","year":"2000","unstructured":"Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P, et al. Cerebrospinal fluid markers for Alzheimer\u2019s disease evaluated after acute ischemic stroke. J Alzheimers Dis. 2000;2:199\u2013206.","journal-title":"J Alzheimers Dis"},{"key":"2709_CR61","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1212\/01.wnl.0000242732.06714.0f","volume":"67","author":"M Ost","year":"2006","unstructured":"Ost M, Nyl\u00e9n K, Csajbok L, Ohrfelt AO, Tullberg M, Wikkels\u00f6 C, et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology. 2006;67:1600\u20134.","journal-title":"Neurology"},{"key":"2709_CR62","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/jamaneurol.2013.6455","volume":"71","author":"T Skillb\u00e4ck","year":"2014","unstructured":"Skillb\u00e4ck T, Ros\u00e9n C, Asztely F, Mattsson N, Blennow K, Zetterberg H. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol. 2014;71:476\u201383.","journal-title":"JAMA Neurol"},{"key":"2709_CR63","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1001\/jamaneurol.2017.2814","volume":"74","author":"S Janelidze","year":"2017","unstructured":"Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, et al. Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol. 2017;74:1492\u2013501.","journal-title":"JAMA Neurol"},{"key":"2709_CR64","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14:1470\u201381.","journal-title":"Alzheimers Dement"},{"key":"2709_CR65","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/archneurol.2008.596","volume":"66","author":"T Tapiola","year":"2009","unstructured":"Tapiola T, Alafuzoff I, Herukka S-K, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid \u03b2-Amyloid 42 and tau proteins as biomarkers of alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382\u20139.","journal-title":"Arch Neurol"},{"key":"2709_CR66","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/brain\/awl269","volume":"129","author":"K Buerger","year":"2006","unstructured":"Buerger K, Ewers M, Pirttil\u00e4 T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer\u2019s disease. Brain. 2006;129:3035\u201341.","journal-title":"Brain"},{"key":"2709_CR67","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.neurobiolaging.2011.02.022","volume":"33","author":"LC de Souza","year":"2012","unstructured":"de Souza LC, Chupin M, Lamari F, Jardel C, Leclercq D, Colliot O, et al. CSF tau markers are correlated with hippocampal volume in Alzheimer\u2019s disease. Neurobiol Aging. 2012;33:1253\u20137.","journal-title":"Neurobiol Aging"},{"key":"2709_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat Commun. 2020;11:1683.","journal-title":"Nat Commun"},{"key":"2709_CR69","doi-asserted-by":"publisher","first-page":"103836","DOI":"10.1016\/j.ebiom.2022.103836","volume":"76","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Benedet AL, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Brum WS, et al. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer\u2019s disease. EBioMedicine. 2022;76:103836.","journal-title":"EBioMedicine."},{"key":"2709_CR70","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3233\/JAD-141725","volume":"44","author":"JL Seeburger","year":"2015","unstructured":"Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, et al. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer\u2019s disease from other dementias and healthy controls in the OPTIMA cohort. J Alzheimers Dis. 2015;44:525\u201339.","journal-title":"J Alzheimers Dis"},{"key":"2709_CR71","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s43587-023-00380-7","volume":"3","author":"NR Barth\u00e9lemy","year":"2023","unstructured":"Barth\u00e9lemy NR, Saef B, Li Y, Gordon BA, He Y, Horie K, et al. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease. Nat Aging. 2023;3:391\u2013401.","journal-title":"Nat Aging"},{"key":"2709_CR72","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie K, Salvad\u00f3 G, Barth\u00e9lemy NR, Janelidze S, Li Y, He Y, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat Med. 2023;29:1954\u201363.","journal-title":"Nat Med"},{"key":"2709_CR73","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1074\/mcp.RA118.001290","volume":"18","author":"A Lle\u00f3","year":"2019","unstructured":"Lle\u00f3 A, N\u00fa\u00f1ez-Llaves R, Alcolea D, Chiva C, Balateu-Pa\u00f1os D, Colom-Cadena M, et al. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer\u2019s disease cerebrospinal fluid. Mol Cell Proteomics. 2019;18:546\u201360.","journal-title":"Mol Cell Proteomics"},{"key":"2709_CR74","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3233\/JAD-210147","volume":"82","author":"MV Lourenco","year":"2021","unstructured":"Lourenco MV, Ribeiro FC, Santos LE, Beckman D, Melo HM, Sudo FK, et al. Cerebrospinal fluid neurotransmitters, cytokines, and chemokines in Alzheimer\u2019s and Lewy body diseases. J Alzheimers Dis. 2021;82:1067\u201374.","journal-title":"J Alzheimers Dis"},{"key":"2709_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01901-5","volume":"12","author":"K Henjum","year":"2022","unstructured":"Henjum K, Watne LO, Godang K, Halaas NB, Eldholm RS, Blennow K, et al. Cerebrospinal fluid catecholamines in Alzheimer\u2019s disease patients with and without biological disease. Transl Psychiatry. 2022;12:151.","journal-title":"Transl Psychiatry"},{"key":"2709_CR76","first-page":"e12034","volume":"12","author":"MV Lourenco","year":"2020","unstructured":"Lourenco MV, Ribeiro FC, Sudo FK, Drummond C, Assun\u00e7\u00e3o N, Vanderborght B, et al. Cerebrospinal fluid irisin correlates with amyloid\u2010\u03b2, BDNF, and cognition in Alzheimer\u2019s disease. Alzheimers Dement Diagn Assess Dis Monit. 2020;12:e12034.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"2709_CR77","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41591-018-0275-4","volume":"25","author":"MV Lourenco","year":"2019","unstructured":"Lourenco MV, Frozza RL, de Freitas GB, Zhang H, Kincheski GC, Ribeiro FC, et al. Exercise-linked FNDC5\/irisin rescues synaptic plasticity and memory defects in Alzheimer\u2019s models. Nat Med. 2019;25:165\u201375.","journal-title":"Nat Med"},{"key":"2709_CR78","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1212\/WNL.0000000000006082","volume":"91","author":"S Janelidze","year":"2018","unstructured":"Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91:e867\u201377.","journal-title":"Neurology"},{"key":"2709_CR79","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3233\/JAD-200394","volume":"77","author":"MM Blazel","year":"2020","unstructured":"Blazel MM, Lazar KK, Van Hulle CA, Ma Y, Cole A, Spalitta A, et al. Factors associated with lumbar puncture participation in Alzheimer\u2019s disease research. J Alzheimers Dis. 2020;77:1559\u201367.","journal-title":"J Alzheimers Dis"},{"key":"2709_CR80","volume":"2019","author":"D Judge","year":"2019","unstructured":"Judge D, Roberts J, Khandker RK, Ambegaonkar B, Black CM. Physician practice patterns associated with diagnostic evaluation of patients with suspected mild cognitive impairment and Alzheimer\u2019s disease. Int J Alzheimer\u2019s Dis. 2019;2019:e4942562.","journal-title":"Int J Alzheimer\u2019s Dis"},{"key":"2709_CR81","first-page":"111","volume":"8","author":"S Engelborghs","year":"2017","unstructured":"Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement Diagn Assess Dis Monit. 2017;8:111\u201326.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"2709_CR82","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","volume":"76","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related \u03b2-amyloid status. JAMA Neurol. 2019;76:1060\u20139.","journal-title":"JAMA Neurol"},{"key":"2709_CR83","first-page":"434","volume":"144","author":"A Keshavan","year":"2021","unstructured":"Keshavan A, Pannee J, Karikari TK, Rodriguez JL, Ashton NJ, Nicholas JM, et al. Population-based blood screening for preclinical Alzheimer\u2019s disease in a British birth cohort at age 70. Brain. 2021;144:434\u201349.","journal-title":"Brain"},{"key":"2709_CR84","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab008","volume":"3","author":"D Tosun","year":"2021","unstructured":"Tosun D, Veitch D, Aisen P, Jack CR Jr, Jagust WJ, et al. Detection of \u03b2-amyloid positivity in Alzheimer\u2019s disease neuroimaging initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Commun. 2021;3:fcab008.","journal-title":"Brain Commun"},{"key":"2709_CR85","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature. 2018;554:249\u201354.","journal-title":"Nature"},{"key":"2709_CR86","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647\u201359.","journal-title":"Neurology"},{"key":"2709_CR87","doi-asserted-by":"publisher","first-page":"e228392","DOI":"10.1001\/jamanetworkopen.2022.8392","volume":"5","author":"Y Hu","year":"2022","unstructured":"Hu Y, Kirmess KM, Meyer MR, Rabinovici GD, Gatsonis C, Siegel BA, et al. Assessment of a plasma amyloid probability score to estimate amyloid positron emission tomography findings among adults with cognitive impairment. JAMA Netw Open. 2022;5:e228392.","journal-title":"JAMA Netw Open"},{"key":"2709_CR88","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/ana.21843","volume":"67","author":"JC Morris","year":"2010","unstructured":"Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122\u201331.","journal-title":"Ann Neurol"},{"key":"2709_CR89","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer\u2019s association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2022;18:2669\u201386.","journal-title":"Alzheimers Dement"},{"key":"2709_CR90","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","volume":"9","author":"N Mattsson","year":"2013","unstructured":"Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer\u2019s association quality control program. Alzheimers Dement. 2013;9:251\u201361.","journal-title":"Alzheimers Dement"},{"key":"2709_CR91","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-021-00942-0","volume":"14","author":"AL Benedet","year":"2022","unstructured":"Benedet AL, Brum WS, Hansson O, Karikari TK, Zimmer ER, Zetterberg H, et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimers Res Ther. 2022;14:26.","journal-title":"Alzheimers Res Ther"},{"key":"2709_CR92","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke MM, Frank RD, Dage JL, Jeromin A, Ashton NJ, Blennow K, et al. Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 2021;78:1108\u201317.","journal-title":"JAMA Neurol"},{"key":"2709_CR93","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","volume":"18","author":"TK Karikari","year":"2022","unstructured":"Karikari TK, Ashton NJ, Brinkmalm G, Brum WS, Benedet AL, Montoliu-Gaya L, et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol. 2022;18:400\u201318.","journal-title":"Nat Rev Neurol"},{"key":"2709_CR94","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26:379\u201386.","journal-title":"Nat Med"},{"key":"2709_CR95","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387\u201397.","journal-title":"Nat Med"},{"key":"2709_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-021-01709-9","volume":"11","author":"X-N Shen","year":"2021","unstructured":"Shen X-N, Huang Y-Y, Chen S-D, Guo Y, Tan L, Dong Q, et al. Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer\u2019s amyloid, tau and FDG PET status. Transl Psychiatry. 2021;11:1\u201310.","journal-title":"Transl Psychiatry"},{"key":"2709_CR97","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13195-023-01319-1","volume":"15","author":"F Mart\u00ednez-Dubarbie","year":"2023","unstructured":"Mart\u00ednez-Dubarbie F, Guerra-Ruiz A, L\u00f3pez-Garc\u00eda S, Lage C, Fern\u00e1ndez-Matarrubia M, Infante J, et al. Accuracy of plasma A\u03b240, A\u03b242, and p-tau181 to detect CSF Alzheimer\u2019s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform. Alzheimers Res Ther. 2023;15:163.","journal-title":"Alzheimers Res Ther"},{"key":"2709_CR98","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","volume":"140","author":"J Lantero Rodriguez","year":"2020","unstructured":"Lantero Rodriguez J, Karikari TK, Su\u00e1rez-Calvet M, Troakes C, King A, Emersic A, et al. Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 2020;140:267\u201378.","journal-title":"Acta Neuropathol"},{"key":"2709_CR99","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/acn3.51695","volume":"10","author":"TF Tropea","year":"2023","unstructured":"Tropea TF, Waligorska T, Xie SX, Nasrallah IM, Cousins KAQ, Trojanowski JQ, et al. Plasma phosphorylated tau181 predicts cognitive and functional decline. Ann Clin Transl Neurol. 2023;10:18\u201331.","journal-title":"Ann Clin Transl Neurol"},{"key":"2709_CR100","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1212\/WNL.0000000000201479","volume":"100","author":"V Planche","year":"2023","unstructured":"Planche V, Bouteloup V, Pellegrin I, Mangin J-F, Dubois B, Ousset P-J, et al. Validity and performance of blood biomarkers for Alzheimer disease to predict dementia risk in a large clinic-based cohort. Neurology. 2023;100:e473\u201384.","journal-title":"Neurology"},{"key":"2709_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42596-6","volume":"14","author":"H Cai","year":"2023","unstructured":"Cai H, Pang Y, Fu X, Ren Z, Jia L. Plasma biomarkers predict Alzheimer\u2019s disease before clinical onset in Chinese cohorts. Nat Commun. 2023;14:6747.","journal-title":"Nat Commun"},{"key":"2709_CR102","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","volume":"26","author":"TK Karikari","year":"2021","unstructured":"Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Su\u00e1rez-Calvet M, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s disease neuroimaging initiative. Mol Psychiatry. 2021;26:429\u201342.","journal-title":"Mol Psychiatry"},{"key":"2709_CR103","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, Barth\u00e9lemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2023;146:1592\u2013601.","journal-title":"Brain"},{"key":"2709_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-51334-x","volume":"14","author":"P Kivis\u00e4kk","year":"2024","unstructured":"Kivis\u00e4kk P, Fatima HA, Cahoon DS, Otieno B, Chacko L, Minooei F, et al. Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer\u2019s disease. Sci Rep. 2024;14:629.","journal-title":"Sci Rep"},{"key":"2709_CR105","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200861","volume":"217","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J Exp Med. 2020;217:e20200861.","journal-title":"J Exp Med"},{"key":"2709_CR106","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20:739\u201352.","journal-title":"Lancet Neurol"},{"key":"2709_CR107","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772\u201381.","journal-title":"JAMA"},{"key":"2709_CR108","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/alz.12301","volume":"17","author":"AM Brickman","year":"2021","unstructured":"Brickman AM, Manly JJ, Honig LS, Sanchez D, Reyes-Dumeyer D, Lantigua RA, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 2021;17:1353\u201364.","journal-title":"Alzheimers Dement"},{"key":"2709_CR109","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvad\u00f3 G, Ossenkoppele R, Ashton NJ, Beach TG, Serrano GE, Reiman EM, et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol Med. 2023;15:e17123.","journal-title":"EMBO Mol Med"},{"key":"2709_CR110","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, et al. Associations of plasma Phospho-Tau217 levels with tau positron emission tomography in early alzheimer disease. JAMA Neurol. 2021;78:149\u201356.","journal-title":"JAMA Neurol"},{"key":"2709_CR111","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy NR, Salvad\u00f3 G, Schindler SE, He Y, Janelidze S, Collij LE, et al. Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. 2024;30:1085\u201395.","journal-title":"Nat Med"},{"key":"2709_CR112","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain. 2020;143:3234\u201341.","journal-title":"Brain"},{"key":"2709_CR113","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141:709\u201324.","journal-title":"Acta Neuropathol"},{"key":"2709_CR114","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/acn3.51553","volume":"9","author":"SD Meyer","year":"2022","unstructured":"Meyer SD, Vanbrabant J, Schaeverbeke JM, Reinartz M, Luckett ES, Dupont P, et al. Phospho\u2010specific plasma p\u2010tau181 assay detects clinical as well as asymptomatic Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2022;9:734.","journal-title":"Ann Clin Transl Neurol"},{"key":"2709_CR115","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1002\/alz.13026","volume":"19","author":"J Therriault","year":"2023","unstructured":"Therriault J, Servaes S, Tissot C, Rahmouni N, Ashton NJ, Bened AL, et al. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:4967\u201377.","journal-title":"Alzheimers Dement"},{"key":"2709_CR116","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, Salvad\u00f3 G, Ortiz-Romero P, Montoliu-Gaya L, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28:1797\u2013801.","journal-title":"Nat Med"},{"key":"2709_CR117","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Salvad\u00f3 G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol. 2023;80:360\u20139.","journal-title":"JAMA Neurol"},{"key":"2709_CR118","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/brain\/awac407","volume":"146","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz F, Turton M, Kac PR, Smirnov D, Premi E, Ghidoni R, et al. Brain-derived tau: a novel blood-based biomarker for Alzheimer\u2019s disease-type neurodegeneration. Brain. 2023;146:1152\u201365.","journal-title":"Brain"},{"key":"2709_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47286-5","volume":"15","author":"F Gonzalez-Ortiz","year":"2024","unstructured":"Gonzalez-Ortiz F, Kirsebom B-E, Contador J, Tanley JE, Selnes P, G\u00edslad\u00f3ttir B, et al. Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer\u2019s disease. Nat Commun. 2024;15:2908.","journal-title":"Nat Commun"},{"key":"2709_CR120","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954\u201363.","journal-title":"Nat Med"},{"key":"2709_CR121","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 2022;21:66\u201377.","journal-title":"Lancet Neurol"},{"key":"2709_CR122","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1002\/alz.13697","volume":"20","author":"H Huber","year":"2024","unstructured":"Huber H, Blennow K, Zetterberg H, Boada M, Jeromin A, Weninger H, et al. Biomarkers of Alzheimer\u2019s disease and neurodegeneration in dried blood spots\u2014a new collection method for remote settings. Alzheimers Dement. 2024;20:2340\u201352.","journal-title":"Alzheimers Dement"},{"key":"2709_CR123","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11682-016-9523-8","volume":"11","author":"MEI Koran","year":"2017","unstructured":"Koran MEI, Wagener M, Hohman TJ, Alzheimer\u2019s Neuroimaging Initiative Sex differences in the association between AD biomarkers and cognitive decline. Brain Imaging Behav. 2017;11:205\u201313.","journal-title":"Brain Imaging Behav"},{"key":"2709_CR124","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD, Algeciras-Schimnich A, Knopman DS, Lowe VJ, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022;28:1398\u2013405.","journal-title":"Nat Med"},{"key":"2709_CR125","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/alz.12647","volume":"19","author":"SE O\u2019Bryant","year":"2023","unstructured":"O\u2019Bryant SE, Petersen M, Hall J, Johnson LA, Team for the H-HS Medical comorbidities and ethnicity impact plasma Alzheimer\u2019s disease biomarkers: Important considerations for clinical trials and practice. Alzheimers Dement. 2023;19:36\u201343.","journal-title":"Alzheimers Dement"},{"key":"2709_CR126","doi-asserted-by":"publisher","first-page":"e1402","DOI":"10.1212\/WNL.0000000000207675","volume":"101","author":"VK Ramanan","year":"2023","unstructured":"Ramanan VK, Graff-Radford J, Syrjanen J, Shir D, Algeciras-Schimnich A, Lucas J, et al. Association of plasma biomarkers of Alzheimer disease with cognition and medical comorbidities in a biracial cohort. Neurology. 2023;101:e1402\u201311.","journal-title":"Neurology"},{"key":"2709_CR127","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/alz.12466","volume":"18","author":"JA Syrjanen","year":"2022","unstructured":"Syrjanen JA, Campbell MR, Algeciras-Schimnich A, Vemuri P, Graff-Radford J, Machulda MM, et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. 2022;18:1128\u201340.","journal-title":"Alzheimers Dement"},{"key":"2709_CR128","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette A, Janelidze S, Cullen N, Dage JL, Bateman RJ, Zetterberg H, et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2023;19:1403\u201314.","journal-title":"Alzheimers Dement"},{"key":"2709_CR129","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1002\/alz.13722","volume":"20","author":"RC Mohs","year":"2024","unstructured":"Mohs RC, Beauregard D, Dwyer J, Gaudioso J, Bork J, MaGee-Rodgers T, et al. The Bio-Hermes study: biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer\u2019s disease. Alzheimers Dement. 2024;20:2752\u201365.","journal-title":"Alzheimers Dement"},{"key":"2709_CR130","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/clinchem\/hvab192","volume":"67","author":"X Wu","year":"2021","unstructured":"Wu X, Xiao Z, Yi J, Ding S, Gu H, Wu W, et al. Development of a plasma biomarker diagnostic model incorporating ultrasensitive digital immunoassay as a screening strategy for Alzheimer disease in a Chinese population. Clin Chem. 2021;67:1628\u201339.","journal-title":"Clin Chem"},{"key":"2709_CR131","doi-asserted-by":"publisher","first-page":"e238214","DOI":"10.1001\/jamanetworkopen.2023.8214","volume":"6","author":"LS Honig","year":"2023","unstructured":"Honig LS, Kang MS, Lee AJ, Reyes-Dumeyer D, Piriz A, Soriano B, et al. Evaluation of plasma biomarkers for A\/T\/N classification of Alzheimer disease among adults of caribbean hispanic ethnicity. JAMA Netw Open. 2023;6:e238214.","journal-title":"JAMA Netw Open"},{"key":"2709_CR132","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1083\/jcb.201211138","volume":"200","author":"G Raposo","year":"2013","unstructured":"Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200:373\u201383.","journal-title":"J Cell Biol"},{"key":"2709_CR133","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","volume":"19","author":"G van Niel","year":"2018","unstructured":"van Niel G, D\u2019Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213\u201328.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2709_CR134","volume":"12","author":"A Badhwar","year":"2020","unstructured":"Badhwar A, Haqqani AS. Biomarker potential of brain-secreted extracellular vesicles in blood in Alzheimer\u2019s disease. Alzheimers Dement Diagn Assess Dis Monit. 2020;12:e12001.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"2709_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1254834","volume":"10","author":"A Manolopoulos","year":"2023","unstructured":"Manolopoulos A, Delgado-Peraza F, Mustapic M, Pucha KA, Nogueras-Ortiz C, Daskalopoulos A, et al. Comparative assessment of Alzheimer\u2019s disease-related biomarkers in plasma and neuron-derived extracellular vesicles: a nested case-control study. Front Mol Biosci. 2023;10:1254834.","journal-title":"Front Mol Biosci"},{"key":"2709_CR136","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1096\/fj.201600816R","volume":"30","author":"EJ Goetzl","year":"2016","unstructured":"Goetzl EJ, Kapogiannis D, Schwartz JB, Lobach IV, Goetzl L, Abner EL, et al. Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer\u2019s disease. FASEB J. 2016;30:4141\u20138.","journal-title":"FASEB J"},{"key":"2709_CR137","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/hbm.23494","volume":"38","author":"RJ Mullins","year":"2017","unstructured":"Mullins RJ, Mustapic M, Goetzl EJ, Kapogiannis D. Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer\u2019s disease. Hum Brain Mapp. 2017;38:1933\u201340.","journal-title":"Hum Brain Mapp"},{"key":"2709_CR138","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1002\/alz.13055","volume":"19","author":"A Kumar","year":"2023","unstructured":"Kumar A, Su Y, Sharma M, Singh S, Kim S, Peavey JJ, et al. MicroRNA expression in extracellular vesicles as a novel blood-based biomarker for Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:4952\u201366.","journal-title":"Alzheimers Dement"},{"key":"2709_CR139","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00216-022-04174-5","volume":"415","author":"TS Martins","year":"2023","unstructured":"Martins TS, Vaz M, Henriques AG. A review on comparative studies addressing exosome isolation methods from body fluids. Anal Bioanal Chem. 2023;415:1239\u201363.","journal-title":"Anal Bioanal Chem"},{"key":"2709_CR140","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.mcn.2005.12.003","volume":"31","author":"J Faur\u00e9","year":"2006","unstructured":"Faur\u00e9 J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, et al. Exosomes are released by cultured cortical neurones. Mol Cell Neurosci. 2006;31:642\u20138.","journal-title":"Mol Cell Neurosci"},{"key":"2709_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114486","volume":"190","author":"C Vandendriessche","year":"2022","unstructured":"Vandendriessche C, Kapogiannis D, Vandenbroucke RE. Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer\u2019s disease. Adv Drug Deliv Rev. 2022;190:114486.","journal-title":"Adv Drug Deliv Rev"},{"key":"2709_CR142","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41592-021-01174-8","volume":"18","author":"M Norman","year":"2021","unstructured":"Norman M, Ter-Ovanesyan D, Trieu W, Lazarovits R, Kowal EJK, Lee JH, et al. L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma. Nat Methods. 2021;18:631\u20134.","journal-title":"Nat Methods"},{"key":"2709_CR143","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adi3647","volume":"9","author":"Y You","year":"2023","unstructured":"You Y, Zhang Z, Sultana N, Ericsson M, Martens YA, Sun M, et al. ATP1A3 as a target for isolating neuron-specific extracellular vesicles from human brain and biofluids. Sci Adv. 2023;9:eadi3647.","journal-title":"Sci Adv"},{"key":"2709_CR144","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s40478-019-0795-2","volume":"7","author":"CD Whelan","year":"2019","unstructured":"Whelan CD, Mattsson N, Nagle MW, Vijayaraghavan S, Hyde C, Janelidze S, et al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer\u2019s disease. Acta Neuropathol Commun. 2019;7:169.","journal-title":"Acta Neuropathol Commun"},{"key":"2709_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42834-x","volume":"14","author":"W Feng","year":"2023","unstructured":"Feng W, Beer JC, Hao Q, Ariyapala IS, Sahajan A, Komarov A, et al. NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. Nat Commun. 2023;14:7238.","journal-title":"Nat Commun"},{"key":"2709_CR146","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jalz.2014.06.008","volume":"11","author":"MS Fiandaca","year":"2015","unstructured":"Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, et al. Identification of preclinical Alzheimer\u2019s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case\u2010control study. Alzheimers Dement. 2015;11:600.","journal-title":"Alzheimers Dement"},{"key":"2709_CR147","first-page":"63","volume":"3","author":"CN Winston","year":"2016","unstructured":"Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, et al. Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimers Dement Diagn Assess Dis Monit. 2016;3:63\u201372.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"2709_CR148","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jalz.2019.05.002","volume":"15","author":"L Jia","year":"2019","unstructured":"Jia L, Qiu Q, Zhang H, Chu L, Du Y, Zhang J, et al. Concordance between the assessment of A\u03b242, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement. 2019;15:1071\u201380.","journal-title":"Alzheimers Dement"},{"key":"2709_CR149","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13195-022-01010-x","volume":"14","author":"T-R Li","year":"2022","unstructured":"Li T-R, Yao Y-X, Jiang X-Y, Dong Q-Y, Yu X-F, Wang T, et al. \u03b2-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer\u2019s disease and predicts cerebral amyloidosis. Alzheimers Res Ther. 2022;14:66.","journal-title":"Alzheimers Res Ther"},{"key":"2709_CR150","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1096\/fj.14-262048","volume":"29","author":"D Kapogiannis","year":"2015","unstructured":"Kapogiannis D, Boxer A, Schwartz JB, Abner EL, Biragyn A, Masharani U, et al. Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer\u2019s disease. FASEB J. 2015;29:589\u201396.","journal-title":"FASEB J"},{"key":"2709_CR151","first-page":"87","volume":"31","author":"YT Ting","year":"2018","unstructured":"Ting YT, Geng LC, Chao GS, Yi Z, Chang WP. The serum exosome derived MicroRNA-135a, -193b, and-384 were potential Alzheimer\u2019s disease biomarkers. Biomed Environ Sci. 2018;31:87\u201396.","journal-title":"Biomed Environ Sci"},{"key":"2709_CR152","doi-asserted-by":"publisher","first-page":"114061","DOI":"10.1016\/j.celrep.2024.114061","volume":"43","author":"LS Ransom","year":"2024","unstructured":"Ransom LS, Liu CS, Dunsmore E, Palmer CR, Nicodemus J, Ziomek D, et al. Human brain small extracellular vesicles contain selectively packaged, full-length mRNA. Cell Rep. 2024;43:114061.","journal-title":"Cell Rep"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02709-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02709-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02709-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T15:04:00Z","timestamp":1734361440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02709-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":152,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2709"],"URL":"https:\/\/doi.org\/10.1038\/s41380-024-02709-z","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"24 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}